Catalyst Event
Sanofi (SNY) · Other
From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)
3/18/2026, 12:00:00 AM
Sanofi's Phase 3 clinical trial (COAST 2) for amlitelimab in atopic dermatitis was updated as completed on March 18, 2026, signaling that top-line data results are expected to be released soon.
Korean Translation
사노피의 아토피 피부염 치료제 암리텔리맙에 대한 3상 임상시험(COAST 2)이 2026년 3월 18일 완료된 것으로 업데이트되어, 주요 데이터 결과 발표가 임박했음을 시사함.
Related Recent Events
CrowdStrike Holdings Inc (CRWD) · Earnings Release
Next earnings release for Q1 2027 is scheduled for 2026-06-09, with analysts forecasting an EPS of $1.07 estimated.
6/9/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Baidu Inc (BIDU) · Earnings Release
Q1 2026 earnings release is scheduled for May 20, 2026. Medium importance is estimated as quarterly earnings typically result in price movements exceeding 5%.
5/20/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Google I/O 2026 developer conference is scheduled for 2026-05-19. Developer conferences usually have a 1-5% price impact. Updates on AI, Gemini, and Android are expected.
5/19/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet is expected to release its Q1 2026 earnings report on April 30, 2026, with analysts forecasting EPS of $0.62 and revenue of $1.73B, scheduled.
4/30/2026, 12:00:00 AM
Automatic Data Processing Inc (ADP) · Earnings Release
Automatic Data Processing is estimated to report its Q3 2026 earnings on or around April 29, 2026, based on past reporting schedules. As earnings reports typically trigger price movements of 5-10%, importance is estimated as Medium, scheduled.
4/29/2026, 12:00:00 AM